Axsome Therapeutics, Inc. (AXSM) - Stock Analysis
Last updated: Apr 5, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Axsome Therapeutics is a hot idea with key upcoming FDA priority review of AXS-05 and NDA filing for AXS-12, strong Q3 revenue growth, and robust technical momentum. Despite operating losses and governance risks, its near-term regulatory catalysts provide potential for significant short-term price appreciation.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠High gross margin ⢠Negative cash flow AXSM has strong liquidity and very high gross margins but is burning cash and reporting large operating losses driven by outsized R&D/SG&A, producing negative returns and elevated leverage despite a cash cushion.
Price Behavior
Key Price Behavior Insights: ⢠Gradual uptrend ⢠Higher lows ⢠Choppy volatility Support Level: $156â$158 Resistance Level: $171.78 AXSM showed a modest upward bias over the last month, recovering from midâMarch lows with higher lows around $156â$158 but failing to sustain above the shortâterm resistance near $171.78 amid elevated, choppy volatility.
Sentiment & News
Key News Insights: ⢠Strong product growth ⢠High insider ownership ⢠Recent stock pullback Axsome's 2025 revenue jump was driven by Auvelity's 74% sales surge to $507M amid heavy insider/institutional ownership and active investor engagement, yet the stock showed short-term weakness after recent earnings.
AI Summary
Axsome has shifted from a binary R&D story to a commercial-growth company where Auvelity-driven revenue momentum and a SUNOSI patent settlement materially de-risk nearâterm outcomes, but the investment hinges on converting high reported revenues into sustained freeâcashâflow through margin recovery. The critical monitoring points are grossâtoânet deterioration and SG&A disciplineâif realized pricing stabilizes and sequential FCF improves, upside is meaningful; if discounts widen or cash burn persists, dilution or downside is likely.
Description
Axsome Therapeutics is a U.S.-based biopharmaceutical company developing treatments for central nervous system disorders. Its late-stage pipeline includes a depression candidate (AXS-05) with additional trials in Alzheimer's-related agitation and prior smoking cessation data, a migraine treatment that completed Phase III testing (AXS-07), and Phase III programs for narcolepsy (AXS-12) and fibromyalgia (AXS-14). The company has a research collaboration with Duke University and was founded in 2012 in New York City.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jan 1 | Jan 8 | AXSM | Axsome Therapeutics, Inc. | Axsome Therapeutics is a hot idea with key upcoming FDA priority review of AXS-05 and NDA filing for AXS-12, strong Q3 revenue growth, and robust technical momentum. Despite operating losses and governance risks, its near-term regulatory catalysts provide potential for significant short-term price appreciation. | Closed | -8.3% |